Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma

Leukemia

Volumn 13, Issue 3, 1999, Pages 453-459

  Moller M B ^b   Ino, Y ^a   Gerdes, A M ^c   Skjodt K ^c   Louis, D N ^a   Pedersen, N T ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c NONE

Author keywords

Diffuse large B cell non Hodgkin's lymphoma; MDM2; p15; p16; p19(ARF); p53

Indexed keywords

PROTEIN MDM2; PROTEIN P16; PROTEIN P53;

ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; CPG ISLAND; DELETION MUTANT; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033013596     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401315     Document Type: Article

References (50)

1. Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672-1677.
2. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996; 10: 1054-1072.
3. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997; 387: 296-299.
4. Thut CJ, Goodrich JA, Tjian R. Repression of p53-mediated transcription by mdm2: a dual mechanism. Genes Dev 1997; 11: 1974-1986.
5. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92: 713-723.
6. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
7. INK4A transcript. Cancer Res 1995; 55: 2995-2997.
8. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A. Complex structure and regulation of the P16(MTS1) locus. Cancer Res 1995; 55: 2988-2994.
9. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: 2231-2234.
10. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res 1993; 53: 2736-2739.
11. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992; 52: 5432s-5440s.
12. Magrath IT (ed). The non-Hodgkin's lymphomas: an introduction. The Non-Hodgkin's Lymphomas. Edward Arnold: London, 1990, pp 1-14.
13. Siebert R, Willers CP, Opalka B. Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma. Leuk Lymphoma 1996; 23: 505-520.
14. Preudhomme C, Fenaux P. The clinial significance of mutations of the p53 tumor suppressor gene in haematological malignancies. Br J Haematol 1997; 98: 502-511.
15. Maestro R, Gloghini A, Doglioni C, Gasparotto D, Vukosavljevic T, De Re V. MDM2 overexpression does not account for stabilization of wild-type p53 protein in non-Hodgkin's lymphomas. Blood 1995; 85: 3239-3246.
16. Kawamata N, Miller C, Levy V, Shintaku IP, Koeffler HP, Said JW. mdm-2 oncogene expression in non-Hodgkin's lymphomas. Diagn Mol Pathol 1996; 5: 33-38.
17. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Piris MA, Ralfkiær E, Warnke RA. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
18. Stansfeld AG, Diebold J, Noel H, Kapanci Y, Rilke F, Kelenyi G, Sundstrom C, Lennert K, van Unnik JA, Mioduszewska O, Wright DH. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292-293.
19. Burns KL, Ueki K, Jhung SL, Koh J, Louis DN. Molecular genetic correlates of p16, cdk4, and pRb immunohistochemistry in glioblastomas. J Neuropathol Exp Neurol 1998; 57: 122-130.
20. Ono Y, Tamiya T, Ichikawa T, Kunishio K, Matsumoto K, Furuta T, Ohmoto T, Ueki K, Louis DN. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices. J Neuropathol Exp Neurol 1996; 55: 1026-1031.
21. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-153.
22. Ueki K, Rubio MP, Ramesh V, Correa KM, Rutter JL, von Deimling A, Buckler AJ, Gusella JF, Louis DN. MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genet 1994; 3: 1841-1845.
23. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996; 93: 8541-8545.
24. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 9821-9826.
25. Guldberg P, Nedergaard T, Nielsen HJ, Olsen AC, Ahrenkiel V, Zeuthen J. Single-step DGGE-based mutation scanning of the p53 gene: application to genetic diagnosis of colorectal cancer. Hum Mutat 1997; 9: 348-355.
26. INK4B in non-Hodgkin's lymphomas. Blood 1995; 86: 1534-1539.
27. Koduru PRK, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood 1995; 86: 2900-2905.
28. INK4A) gene in primary B-cell lymphomas. Blood 1995; 86: 2724-2731.
29. INK4A gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 2977-2984.
30. Stranks G, Height SE, Mitchell P, Jadayel D, Yuille MAR, De Lord C, Clutterbuck RD, Treleaven JG, Powles RL, Nacheva E, Oscier DG, Karpas A, Lenoir GM, Smith SD, Millar JD, Catovsky D, Dyer MJS. Deletions and rearrangements of CDKN2 in lymphoid malignancy. Blood 1995; 85: 893-901.
31. Garcia-Sanz R, Gonzalez M, Vargas M, Chillon MC, Balanzategui A, Barbon M, Flores MT, San Miguel JF. Deletions and rearrangements of cyclin-dependent kinase 4 inhibitor gene p16 are associated with poor prognosis in B cell non-Hodgkin's lymphomas. Leukemia 1997; 11: 1915-1920.
32. Ogawa S, Hangaishi A, Miyawaki S, Hirosawa S, Miura Y, Takeyama K, Kamada N, Ohtake S, Uike N, Shimazaki C, Toyama K, Hirano M, Mizoguchi H, Kobayashi Y, Furusawa S, Saito M, Emi N, Yasaki Y, Ueda R, Hirai H. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 1995; 86: 1548-1556.
33. INK4A characterize the major types of hematological malignancies. Cancer Res 1997; 57: 837-841.
34. Martinez-Delgado B, Fernandez-Piqueras J, Garcia MJ, Arranz E, Gallego J, Rivas C, Robledo M, Benitez J. Hypermethylation of a 5′ CpG island of p16 is a frequent event in non-Hodgkin's lymphoma. Leukemia 1997; 11: 425-428.
35. Martinez JC, Mateo M, Sanchez-Beato M, Villuendas R, Orradre JL, Algara P, Sanchez-Verde L, Garcia P, Lopez C, Martinez P, Piris MA. MDM2 expression in lymphoid cells and reactive and neoplastic lymphoid tissue: comparative study with p53 expression. J Pathol 1995; 177: 27-34.
36. Barak Y, Gottlieb E, Juven-Gershon T, Oren M. Regulation of mdrn2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes Dev 1994; 8: 1739-1749.
37. Olson DC, Marechal V, Momand J, Chen J, Romocki C, Levine AJ. Identification and characterization of multiple mdm-2 proteins and mdm-2-p53 protein complexes. Oncogene 1993; 8: 2353-2360.
38. Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res 1997; 57: 3562-3568.
39. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nature Med 1996; 2: 912-917.
40. Matsumoto R, Tada M, Nozaki M, Zhang CL, Sawamura Y, Abe H. Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms. Cancer Res 1998; 58: 609-613.
41. Schlott T, Reimer S, Jahns A, Ohlenbusch A, Ruschenburg I, Nagel H, Droese M. Point mutations and nucleotide insertions in the MDM2 zinc finger structure of human tumours. J Pathol 1997; 182: 54-61.
42. ARF. Proc Natl Acad Sci USA 1997; 94: 669-673.
43. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JYJ, Huang HJS, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDKN2Aβ alleles: evidence for an RB-independent growth suppressive pathway. Oncogene 1997; 15: 2013-2020.
44. INK4a in primary rat lung tumors. Mol Cell Biol 1997; 17: 1366-1374.
45. INK4 gene. Blood 1996; 87: 1657-1658.
46. INK4a/MTS1 gene. Oncogene 1997; 15: 2475-2481.
47. INK4 (9p21), and DBM (13q14)) in B-cell chronic lymphocytic leukemia. Mol Carcinog 1995; 14: 141-146.
48. INK4B, p53, and Rb genes in primary lymphoid malignancies. Blood 1996; 87: 4949-4958.
49. Wat1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997; 89: 272-280.
50. Cobbers JMJL, Wolter M, Reifenberger J, Ring GU, Jessen F, An HX, Niederacher D, Schmidt EE, Ichimura K, Floeth F, Kirsch L, Borchard F, Louis DN, Collins VP, Reifenberger G. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL. Brain Pathol 1998; 8: 263-276.